• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » INC Research to manage Leukemia & Lymphoma Society umbrella trial

INC Research to manage Leukemia & Lymphoma Society umbrella trial

November 11, 2016
CenterWatch Staff

INC Research, a global phase I to IV CRO, has announced its involvement in The Leukemia & Lymphoma Society’s (LLS) recently-launched precision medicine Master Trial to treat acute myeloid leukemia (AML). The Beat AML Master Trial is breaking ground in a number of areas, including the first time a nonprofit organization is working with multiple biotech and pharma sponsors and other key collaborators to professionally operationalize a study. The trial will provide principal investigators and their patients consolidated access to test novel therapies matched to specific molecular aberrations in AML.

The LLS designed the Beat AML Master Trial as an umbrella trial, which differs from traditional trials in that newly diagnosed AML patients will enter this study based on screening for specific molecular mutations known to be drivers of their disease, and will be matched to a specific targeted therapy for that aberration. The LLS expects the scope of the multi-year trial to include 15 to 20 clinical research sites, up to 10 different treatment arms and 500 patients.

“The Beat AML Master Trial is a significant milestone for LLS, specifically its commitment to helping AML patients, for whom there has not been an advance in standard treatment in more than 40 years,” said Louis J. DeGennaro, Ph.D., LLS president and CEO. “LLS is uniquely able to convene this collaboration, which marks the first time that the organization has functioned as the sponsor of a clinical trial. Working with INC Research will allow us to tap into the Company’s long-established relationships with physicians and medical centers to ensure timely delivery of data, a crucial element of this precision medicine approach.”

INC Research was selected to manage the Beat AML Master Trial based on extensive experience with AML clinical research and the Company’s robust reputation in the field of hematologic malignancies. In the past five years, the company’s Oncology business unit has conducted 40 leukemia studies at more than 1,000 clinical research sites worldwide involving nearly 5,500 patients. INC Research will provide a full range of CRO services for the Master Trial ranging from study startup to project management and clinical operations to biostatistics and medical writing.

“Even though there has been intense clinical trial activity, and research has led to a much deeper understanding of the molecular biology of AML, treatment standards have not been able to advance in the past several years; this remains a disease with poor prognosis,” said Nicholas Kenny, Ph.D., executive vice president and general manager for Oncology at INC Research. “INC’s Oncology team is therefore thrilled to be engaged with LLS in this groundbreaking study. The collaboration LLS has created among biopharma companies, leading AML clinical researchers from the U.S., the FDA and multiple support groups is impressive. We anticipate this will be a landmark trial for AML patients—particularly because it moves multiple targeted therapies into an up-front/newly diagnosed AML setting while concurrently offering physicians and patients a truly targeted approach to the disease.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing